Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases
- 28 October 2012
- journal article
- review article
- Published by Elsevier BV in Cancer Letters
- Vol. 323 (2), 135-146
- https://doi.org/10.1016/j.canlet.2012.04.001
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over?Advances in Urology, 2011
- Expanding Treatment Options for Metastatic Prostate CancerThe New England Journal of Medicine, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2011
- Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancerProstate Cancer and Prostatic Diseases, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerThe New England Journal of Medicine, 2010
- Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate CancerJournal of Clinical Oncology, 2009
- Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2009
- EANM procedure guideline for treatment of refractory metastatic bone painEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Mechanisms of Bone MetastasisThe New England Journal of Medicine, 2004
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993